Pronai Therapeutics (NASDAQ:SRRA)

CAPS Rating: 3 out of 5

Caps

How do you think SRRA will perform against the market?

Add Stock to CAPS Watchlist

All Players

33 Outperform
3 Underperform
 

All-Star Players

15 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top SRRA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.62)
Submitted June 19, 2016

When I saw the destruction ASCO wreaked on ProNAi, I was relieved I had never added the stock to my database. After declining from highs in the 30's, the stock probably would have looked pretty good to me at 6 going into ASCO. Unfortunately for… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

SRRA VS S&P 500 (SPY)

SRRA Summary

Fools bearish on SRRA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about SRRA.

Recs

0
Member Avatar clangmead (58.02) Submitted: 8/3/2017 9:05:41 AM : Outperform Start Price: $1.48 SRRA Score: +8.69

ML

Recs

0
Member Avatar Ted2400 (40.46) Submitted: 8/6/2016 9:43:23 AM : Outperform Start Price: $1.98 SRRA Score: -38.90

Company has $143 mil in cash market cap only $60 million. A good management team is in place.

Recs

1
Member Avatar zzlangerhans (99.62) Submitted: 6/19/2016 6:32:48 AM : Outperform Start Price: $2.00 SRRA Score: -48.01

When I saw the destruction ASCO wreaked on ProNAi, I was relieved I had never added the stock to my database. After declining from highs in the 30's, the stock probably would have looked pretty good to me at 6 going into ASCO. Unfortunately for anyone who actually did act on that thought, the stock dropped to a low of 1.86 after the company announced they were discontinuing the phase II trial of their lead drug PNT2258 for DLBCL due to weak efficacy. As seems to be the rule these days, price action predicts trial outcome.

The stock now trades at a huge discount to cash, 61M cap vs 141M cash as of the end of March. ProNAi burns about 10M per quarter so it will be two years before the cash declines to the current cap, as long as they don't go the reverse merger route. There appears to still be a phase II trial of PNT2258 in progress, for CLL, and ProNAi recently inlicensed a new preclinical candidate. Portefeuille initiated a position in ProNAi before I'd even had a chance to add the company to my database, and once I got the story I celebrated my prior ignorance of the stock by increasing our position to 10000 shares cost basis 1.96.

Leaderboard

Find the members with the highest scoring picks in SRRA.

Score Leader

swhaze

swhaze (< 20) Score: +130.31

The Score Leader is the player with the highest score across all their picks in SRRA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
swhaze < 20 2/8/2016 Underperform 1Y $7.07 -73.55% +56.76% +130.31 0 Comment
RonaldSpeth1 58.75 6/2/2017 Outperform 5Y $1.12 +66.96% +19.64% +47.33 0 Comment
WildShaman 75.79 7/9/2018 Underperform 5Y $3.00 -37.67% +5.30% +42.97 0 Comment
icebit1 54.50 8/10/2016 Underperform 5Y $1.93 -3.11% +33.40% +36.51 0 Comment
teufelhunden62 93.93 5/10/2017 Outperform 5Y $1.25 +49.60% +21.65% +27.95 0 Comment
ababrmon 93.29 5/2/2017 Outperform 5Y $1.38 +35.51% +22.18% +13.33 0 Comment
clangmead 58.02 8/8/2017 Outperform 5Y $1.48 +26.35% +17.66% +8.69 1 Comment
mistermiranga 99.56 8/29/2018 Outperform 5Y $1.77 +5.95% -0.04% +5.99 0 Comment
beecha 28.81 9/19/2017 Outperform 5Y $1.55 +20.65% +16.49% +4.16 0 Comment
mrmrmrj 56.27 8/31/2017 Outperform 5Y $1.57 +19.11% +18.00% +1.11 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SRRA.

Featured Broker Partners


Advertisement